Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02525653 · ClinicalTrials.gov registry record · Phase 2

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

A Phase 2 study of Lung Cancer and Untreated Stage IV or Recurrent Squamous Cell Lung Cancers, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
6
Study locations

NCT02525653 is a Phase 2 study of Lung Cancer and Untreated Stage IV or Recurrent Squamous Cell Lung Cancers that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02525653, a Phase 2 study of Lung Cancer and Untreated Stage IV or Recurrent Squamous Cell Lung Cancers, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators would like to determine the percentage of patients with squamous cell lung cancers who experience shrinkage of their tumors following treatment with this regimen. This combination of drugs is not a standard therapy for patients with squamous cell lung cancers. However, each of these drugs, when given alone or with other chemotherapies, is FDA-approved for the treatment of this disease.

Conditions Studied

Lung Cancer Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Interventions

  • DRUG gemcitabine
  • DRUG albumin-bound paclitaxel

Study Locations (6)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Rockville Centre - Rockville Centre
  • Memorial Sloan Kettering Westchester - Sleepy Hollow

Florida

  • Miami Cancer Institute Baptist Health South Florida - Miami

New Jersey

  • Memorial Sloan Kettering at Basking Ridge - Basking Ridge

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2015-08
Est. Completion 2019-05
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02525653

The ClinicalTrials.gov registry entry for NCT02525653 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.

NCT02525653 reports 6 study locations spanning 3 distinct geographic areas - top geographies include New York, Florida, New Jersey.

Frequently Asked Questions

What is clinical trial NCT02525653 about?

NCT02525653 is a clinical study titled "Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers". The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators would like to determine the percentage of patients with squamous cell lung cancers who experience shrinkage of their ...

What is the current status of trial NCT02525653?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-08. Estimated completion is 2019-05.

What conditions does trial NCT02525653 study?

This clinical trial studies the following conditions: Lung Cancer, Untreated Stage IV or Recurrent Squamous Cell Lung Cancers.

What interventions are being tested in trial NCT02525653?

The interventions under investigation include: gemcitabine (DRUG), albumin-bound paclitaxel (DRUG).

Who is sponsoring clinical trial NCT02525653?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02525653 being conducted?

This trial has 6 study locations across Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.